Nissay Asset Management Corp Japan ADV Raises Holdings in Johnson & Johnson $JNJ

Key Points

• Nissay Asset Management Corp Japan ADV increased its stake in Johnson & Johnson by 0.9%, owning 309,530 shares valued at $51.33 million after adding an additional 2,810 shares in the first quarter.
• Johnson & Johnson reported a quarterly earnings per share of $2.77, exceeding analysts' expectations, and had a revenue of $23.74 billion, showing a 5.8% year-over-year increase.
• The company also announced a quarterly dividend of $1.30 per share, which represents an annualized dividend yield of 2.9%.

Nissay Asset Management Corp Japan ADV boosted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 0.9% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 309,530 shares of the company's stock after purchasing an additional 2,810 shares during the quarter. Nissay Asset Management Corp Japan ADV's holdings in Johnson & Johnson were worth $51,332,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Elios Financial Group Inc. boosted its stake in Johnson & Johnson by 1.5% during the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after acquiring an additional 66 shares during the last quarter. Atlantic Family Wealth LLC increased its position in Johnson & Johnson by 4.4% during the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock valued at $266,000 after purchasing an additional 67 shares during the period. MBA Advisors LLC grew its position in shares of Johnson & Johnson by 1.2% during the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after buying an additional 68 shares during the period. Sovereign Financial Group Inc. grew its position in Johnson & Johnson by 1.8% in the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after purchasing an additional 69 shares during the period. Finally, Nabity Jensen Investment Management Inc boosted its holdings in Johnson & Johnson by 1.5% during the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock worth $767,000 after acquiring an additional 69 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent analyst reports. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Wall Street Zen downgraded Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Friday. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. UBS Group increased their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Finally, Citigroup increased their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research report on Thursday, August 21st. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average target price of $176.29.

Johnson & Johnson Price Performance

JNJ traded down $0.57 on Friday, hitting $178.20. 9,733,095 shares of the company's stock traded hands, compared to its average volume of 7,556,979. The company's 50 day simple moving average is $168.57 and its 200-day simple moving average is $160.78. The firm has a market cap of $429.15 billion, a price-to-earnings ratio of 19.06, a P/E/G ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter last year, the business posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson's payout ratio is presently 55.61%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.